Neurocrine Biosciences, Inc. Q2 FY26 Results — Earnings Call Analysis

The provided transcript of Neurocrine Biosciences' Q1 2026 earnings call does not mention any current or planned fundraising activities through debt or equity. Key points regarding financial matters include: - No discussion of new debt or equity fundraising during the call. - Focus on strong operating income (around $200 million GAAP and non-GAAP). - Capital allocation priorities emphasize driving revenue growth, advancing the pipeline, and strategic business development. - Pending acquisition of Soleno Therapeutics expected to close in Q2 2026, with no financial guidance yet on the transaction. - No commentary on raising new capital; emphasis on durable cash flows funding ongoing R&D and business development. In summary, there is no indication of current or future fundraising through debt or equity discussed during this earnings call.

The transcript does not specifically mention current or expected orderbook or pending orders in quantitative terms. However, relevant commercial and sales information includes: - CRENESSITY new patient starts remain steady and consistent with positive momentum. - Persistence and compliance rates for CRENESSITY are strong and consistent through about 5 quarters of launch. - Expanded field sales team for CRENESSITY expected to increase prescriber engagement and new patient starts. - INGREZZA showed strong underlying demand and managed seasonality well, with guidance reaffirmed at $2.7B to $2.8B in net product sales for 2026. - Pending addition of VYKAT XR from Soleno Therapeutics acquisition, expected to close in Q2 2026, strengthening commercial portfolio. - Overall, continued broad accumulation of patients and strong prescription growth across portfolio reflected in record quarterly net product sales exceeding $800 million. No explicit orderbook or pending orders numbers were provided.